GI has been the topic of several other research reports. Zacks Investment Research upgraded EndoChoice Holdings from a hold rating to a buy rating and set a $5.25 price target on the stock in a research note on Tuesday, July 5th. JPMorgan Chase & Co. started coverage on EndoChoice Holdings in a research note on Wednesday, July 13th. They issued an overweight rating on the stock. Finally, Stifel Nicolaus decreased their price target on EndoChoice Holdings from $10.00 to $7.00 and set a buy rating on the stock in a research note on Thursday, August 4th. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The company currently has an average rating of Hold and an average target price of $7.42.
Shares of EndoChoice Holdings (NYSE:GI) opened at 7.98 on Friday. The firm’s market cap is $207.86 million. EndoChoice Holdings has a 52-week low of $3.64 and a 52-week high of $12.44. The stock’s 50 day moving average price is $4.90 and its 200-day moving average price is $4.83.
EndoChoice Holdings (NYSE:GI) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.47. EndoChoice Holdings had a negative net margin of 88.94% and a negative return on equity of 62.04%. The business earned $19.30 million during the quarter, compared to the consensus estimate of $20.67 million. During the same quarter in the previous year, the business posted ($1.01) EPS. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. On average, analysts forecast that EndoChoice Holdings will post ($2.53) EPS for the current year.
A number of large investors have recently modified their holdings of the company. Iguana Healthcare Management LLC raised its stake in shares of EndoChoice Holdings by 8.7% in the second quarter. Iguana Healthcare Management LLC now owns 125,000 shares of the company’s stock worth $613,000 after buying an additional 10,000 shares in the last quarter. Paloma Partners Management Co purchased a new stake in shares of EndoChoice Holdings during the second quarter worth $161,000. Bridgeway Capital Management Inc. purchased a new stake in shares of EndoChoice Holdings during the second quarter worth $368,000. Spark Investment Management LLC purchased a new stake in shares of EndoChoice Holdings during the second quarter worth $318,000. Finally, Vanguard Group Inc. raised its stake in shares of EndoChoice Holdings by 13.8% in the second quarter. Vanguard Group Inc. now owns 274,967 shares of the company’s stock worth $1,348,000 after buying an additional 33,427 shares in the last quarter. Institutional investors and hedge funds own 37.71% of the company’s stock.
EndoChoice Holdings Company Profile
EndoChoice Holdings, Inc is a medical device company. The Company is focused on designing and commercializing a platform of products and services for gastrointestinal (GI) caregivers. The Company offers a range of products and services that span single-use devices and infection control products, pathology and imaging systems.
Receive News & Ratings for EndoChoice Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EndoChoice Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.